Logan Capital Management Inc. Purchases 6,058 Shares of Novartis AG $NVS

Logan Capital Management Inc. boosted its holdings in shares of Novartis AG (NYSE:NVS) by 11.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,363 shares of the company’s stock after buying an additional 6,058 shares during the quarter. Logan Capital Management Inc.’s holdings in Novartis were worth $8,047,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Arlington Trust Co LLC bought a new position in shares of Novartis during the 4th quarter worth about $25,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Novartis in the 3rd quarter worth approximately $33,000. South Plains Financial Inc. grew its holdings in shares of Novartis by 39.0% during the 3rd quarter. South Plains Financial Inc. now owns 271 shares of the company’s stock worth $35,000 after purchasing an additional 76 shares in the last quarter. Cornerstone Planning Group LLC increased its position in shares of Novartis by 15,950.0% during the fourth quarter. Cornerstone Planning Group LLC now owns 321 shares of the company’s stock valued at $47,000 after purchasing an additional 319 shares during the period. Finally, Aventura Private Wealth LLC acquired a new position in shares of Novartis in the fourth quarter valued at $45,000. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Price Performance

NYSE:NVS opened at $153.96 on Friday. The company has a quick ratio of 0.65, a current ratio of 0.85 and a debt-to-equity ratio of 0.96. The firm has a market cap of $293.77 billion, a PE ratio of 22.06, a price-to-earnings-growth ratio of 2.61 and a beta of 0.46. Novartis AG has a 12 month low of $112.34 and a 12 month high of $170.46. The company’s 50-day moving average price is $149.51 and its two-hundred day moving average price is $148.03.

Novartis (NYSE:NVS) last posted its earnings results on Monday, April 27th. The company reported $1.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). The firm had revenue of $13.52 billion during the quarter, compared to the consensus estimate of $13.44 billion. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The business’s revenue was down .9% on a year-over-year basis. During the same quarter last year, the firm posted $2.28 EPS. On average, equities analysts anticipate that Novartis AG will post 8.83 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on NVS. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a report on Thursday, February 12th. Sanford C. Bernstein upgraded shares of Novartis to a “hold” rating in a research note on Thursday, March 19th. TD Cowen reaffirmed a “hold” rating on shares of Novartis in a report on Tuesday, February 17th. Weiss Ratings lowered Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Finally, Morgan Stanley raised their target price on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research report on Thursday, March 26th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Novartis has an average rating of “Hold” and a consensus target price of $141.20.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.